India Pharma Outlook Team | Thursday, 30 July 2026
Patients with Heart Failure often need hospital visits when fluid builds up in the body.
MannKind now wants to change that with its Autoinjector Pen technology. The company is developing a treatment that could replace IV infusions with a quick subcutaneous injection.
The company aims to replace lengthy IV infusions with a quick subcutaneous injection. The approach could help eligible patients receive treatment at home instead of visiting emergency rooms or infusion centers.
The company has signed a licensing agreement with Cumberland Pharmaceuticals to develop an autoinjector version of ifetroban. MannKind plans to combine the drug with its proprietary delivery technology. The goal is to simplify treatment while improving access for patients living with heart failure.
Heart failure patients often experience fluid buildup in the body. This condition can cause breathing problems, swelling, and repeated hospital visits. Many patients currently need intravenous diuretics in emergency rooms or infusion clinics.
MannKind believes its new treatment could offer a faster and more convenient alternative. The company plans to use its autoinjector platform to deliver ifetroban under the skin. The injection is designed for easy administration outside a hospital setting.
If successful, the treatment may reduce the need for IV infusions. It could also lower pressure on hospitals and improve patient comfort.
According to the company, the agreement gives MannKind exclusive rights to develop and commercialize the autoinjector product using ifetroban for heart failure.
Also Read: India's Path to Billion-Dollar Drugs: Building a Strong Ecosystem
Heart failure affects millions of people worldwide. Many patients require repeated treatment when excess fluid builds up. Hospital visits can be expensive, stressful, and time-consuming.
An autoinjector could allow eligible patients to receive therapy earlier. Faster treatment may help prevent symptoms from becoming severe enough to require emergency care. The product is still under development. Clinical studies and regulatory approvals will be needed before it becomes available for patients.
The announcement reflects a growing trend toward home-based care. Drug developers are increasingly focusing on treatments that reduce hospital dependence.
MannKind is widely known for developing innovative drug delivery technologies. The company has expanded beyond inhaled therapies by investing in injectable delivery platforms.
The partnership with Cumberland Pharmaceuticals supports that strategy. Cumberland developed ifetroban for several cardiovascular conditions. MannKind will now explore its use through an autoinjector designed for heart failure patients.
If development progresses successfully, the product could become another option for patients who need rapid treatment without hospital admission.
The planned autoinjector reflects the industry's shift toward patient-friendly therapies. If approved, it could offer heart failure patients a more convenient way to receive treatment while reducing reliance on hospital-based IV care.
